Advertisement


Anders Widmark, MD, PhD, on Intermediate-Risk Prostate Cancer: Results From the HYPO-RT-PC Trial

2016 ASTRO Annual Meeting

Advertisement

Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)



Related Videos

Breast Cancer

Meena Moran, MD, on Ductal Carcinoma In Situ: Improving Local Control

Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local contr...

Lung Cancer

Maria Werner-Wasik, MD, on Issues in Lung Toxicity

Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation ...

Breast Cancer

Douglas W. Arthur, MD, on Breast-Preserving Surgery: Results From NRG Oncology/RTOG 1014

Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial bre...

Issues in Oncology

Lia M. Halasz, MD, on Disparities in Radiotherapy Delivery

Lia M. Halasz, MD, of the University of Washington Seattle Cancer Care Alliance, summarizes a session on the uneven delivery of radiotherapy in the United States and around the world....

Bruce D. Minsky, MD's, Meeting Highlights: An Expert Perspective

Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.

Advertisement

Advertisement



;
Advertisement